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Abstract 
Purpose: To retrospectively elucidate the preliminary clinical impact of warmed 
miriplatin/lipiodol suspension (MPT-LPD) when used as a chemotherapeutic agent of 
transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). 
Materials and Methods: Between June and Dec. 2010, TACE was performed using 
MPT/LPD at room temperature (RT group), and after Jan. 2011, TACE using MPT-
LPD warmed upto 40℃ was performed (W group).  The intraarterial appearance of 
MPT-LPD immediately after injection through microcatheters at the second-order 
branches was compared between the two groups using a 5-point grading system. Local 
therapeutic effects of HCCs as assessed on follow-up computed tomography (CT) 
obtained 1-3 months after TACE were compared between the groups with a 4-point 
grading system (TE1-TE4).  After April 2011, angiography-assisted CT was routinely 
performed at TACE, and HCCs that revealed apparent corona enhancement (CE) were 
retrospectively selected. The degree of concordance between CE and MPT-LPD 
accumulation as assessed by CT immediately after TACE was assessed using 3-point 
grading.  
Results: MPT-LPD therapy resulted in a smooth and continuous appearances in the W 
groups (grades 1, 2, 3, 4, and 5=1, 2, 11, 18, and 4) compared to the RT group (4, 0, 
1, 2, and 0).  The W group (TE1, TE2, TE3, and TE4 were 1, 9, 11, and 12) revealed 
better local therapeutic effects than the RT group (6, 3, 9, and 0) (p < 0.05).  CE was 
found in 29 HCC nodules, and concordance between CE and MPT-LPD accumulation 
was observed in 66% (grade 1, 2, and 3 were, respectively, 2, 8, and 19). 
Conclusion:  Warmed MPT-LPD flowed more smoothly within vascular lumen, passed  
through tumor sinusoid of HCC, and had better local therapeutic effects at short-term 
observation than MPT-LPD at room temperature.   
Introduction 
 Transarterial chemoembolization (TACE) is one of the accepted therapeutic choice 
for hepatocellular carcinomas (HCC), usually indicated for relatively large (> 3cm) or 
multiple (> 3) lesions [1,2].  For TACE, usage of emulsion of chemotherapeutic 
agents, such as epirubicin or cisplatinum, or iodized oil (lipiodol, LPD; Guerbet, 
Villepinte, France) is recommended to enhance anti-cancer effect [1, 2].  To 
maximize the therapeutic effect of TACE, anti-cancer agents with higher solubility 
and stability in LPD, also for gradual release within tumors, are considered ideal.  
Miriplatin (MPT) is theoretically a good candidate for this kind of agent [3, 4]. 
However, in actual clinical practice, many interventional radiologists have pointed 
out that injection of MPT-LPD suspension requires unusually high pressure, 
particularly through a microcatheter system, compared to LPD emulsion with 
conventional chemotherapeutic agents.  This is due to the high viscosity of MPT-
LPD suspension. 
 To overcome this problem, we proposed a warming MPT-LPD method and reported 
its basic in vitro data [5], in which simple warming of MPT-LPD to 40℃ significantly 
reduced its viscosity and thus the injection pressure through microcatheters.  Since 
then, after obtaining institutional review board (IRB) approval, we applied this 
warming method to clinical cases, expecting MPT-LPD would flow more smoothly and 
with less resistance within microcatheters and huma arteries.  The high viscosity of 
MPT-LPD means that it may choke the vessels before reaching HCC lesion, which 
would greatly hamper its antitumor effects, although a lesser antitumor effect of 
MPT-LPD has recently been reported compared to conventional TACE uses 
epirubicine, when used at room temperature [6].   
According to previous investigators [7, 8], anticancer drug emulsions and LPD pass 
through the tumor sinusoids within HCC and reach the peritumoral liver parenchyma 
via venous drainage routes, which enhances the antitumor effect of subsegmental 
TACE by obstructing both the arterial and portal sides of the tumor vascular system.  
On the basis of these concepts, if we could demonstrate that warmed MPT-LPD can 
reach the venous drainage areas around the tumor, namely the areas of corona 
enhancement (CE) [9], it would indirectly suggest that MPT-LPD can pass through 
tumor sinusoids and hence may have sufficient antitumor effect.    
Our current study first addresses the appearances of MPT-LPD within the arteries 
immediately after its injection in patients who underwent TACE with MPT-LPD at 
room temperature (RT group) and with warmed MPT-LPD (W group). We expected 
that the change in viscosity of MPT-LPD would result in a morphological change. 
Second, the degree of MPT-LPD accumulation was compared on the follow-up 
computed tomography (CT) obtained 1-3 months after TACE between RT and W 
groups. Finally, for HCC nodules that exhibited apparent CE on the second phase of 
CT during hepatic arteriography (CTHA), the degree of concordance between MPT-
LPD distribution and CE was assessed by CT obtained immediately after TACE in W 
group.    
Materials and Methods 
Before the IRB approval of clinical use of warmed MPT-LPD, 15 patients had been 
treated with MPT-TACE at room temperature (RT group) between June and 
December 2010.  After we received IRB approval, 37 patients were treated with 
TACE that used MPT-LPD warmed to 40℃ (W group) between January and 
October 2011.  From these patients, further selection was applied for each 
assessment. 
 
 
Assessment of the intraarterial appearance of MPT-LPD 
 
To assess the intraarterial appearance of MPT-LPD, the whole process of MPT-LPD 
injection was routinely recorded via digital subtraction angiography, at three frames 
per second, between September 2010 and March 2011 (Multistar TOP; Siemens, 
Erlangen, Germany).  Two experienced abdominal and interventional radiologists 
blinded to the patients’ information retrospectively reviewed the digital subtraction 
angiographic images with MPT-LPD injection, and treated branches of similar caliber, 
namely second-order branches, were selected for review. The appearance of MPT-
LPD was qualitatively graded into five categories by consensus (Fig. 1).  The grades 
were compared between the two groups by Mann-Whitney test. 
 
Short term local therapeutic effect assessed on follow-up CT 
 
For the patients in both the RT and W groups, follow-up CT examinations after 
TACE were evaluated.  Among these patients, those with nodular HCCs with a total 
sum of diameters less than 6cm were retrospectively selected to exclude patients 
treated with an insufficient amount of MPT-LPD, because the maximum amount of 
MPT-LPD currently approved in Japan is 6ml, and previous report has suggested 
that 1 ml of emulsion of chemotherapeutic agent and lipiodol correspond to 1cm 
diameter of HCC to be treated by TACE [10].   
TACE was performed according to the usual method as reported, as previously 
reported [11].  A 3F coaxial microcatheter was advanced to second-order or more 
peripheral branches of the hepatic artery supplying the tumors, where MPT-LPD was 
injected, followed by injection of 1 mm gelatin sponge particle (GelPart ;Nippon 
Kayaku, Tokyo, Japan), finally obtaining complete stoppage of the arterial flow.  
MPT-LPD injection was performed under fluoroscopic guidance.  At the end of the 
procedure, angiography was repeated to confirm complete disappearance of tumor 
stain. 
Follow-up CT was typically obtained 1-3 months after TACE, depending on the 
condition of the patient, referring to the blood test data, including tumor markersα-
fetoprotein and protein induced by vitamin K absence/antagonist-II.  Parameters for 
CT scanning are as follows: equipment, 64-row multidetector CT (Aquilion 64; 
Toshiba Medical systems, Ootahara, Japan), 0.5mm collimation, 2 mm reconstruction, 
pitch 53, 120 kVp; Auto-mAs: quadruple scanning consisting of precontrast, arterial 
dominant (40 s delay), portal venous (70 s delay), and equilibrium phases (240 s 
delay).  A total of 600 mg I/kg was delivered intraveneously in 30 s with 370 mg 
I/mL contrast medium (Iopamiron 370; BayerHealthCare, Osaka, Japan) or 350 mg 
I/mL contrast medium (Omnipaque 350, Daiichi-Sankyo Co., Tokyo , Japan; or 
Iomeron 350, Eisai Co., Ltd., Tokyo, Japan).  To compare the local therapeutic 
effect of TACE between the RT and W groups, two experienced abdominal and 
interventional radiologists blinded to the patients’ information reviewed and 
evaluated these images in consensus. The degree of LPD accumulation was assessed 
and subclassified into four grades (TE1 through TE4) according to the General Rules 
the Clinical and Pathological Study of Primary Liver Cancer [12] on follow-up CT.  
Definitions of the four grades are as follows; TE1, tumor enlargement more than 25 %;   
TE2, tumor response between TE1 and TE3; TE3, tumor necrosis or dense LPD  
accumulation of more than 50 %; and TE4, difuse accumulation of LPD associated 
with tumor size reduction, suggesting100% tumor necrosis. 
  The severity of postembolization syndrome was compared between the groups 
using the maximum level of C-reactive protein after TACE and duration of 
hospitalization, in days, as arbitrary indices.   
 
 
Evaluation of LPD Distribution Immediately after TACE in correlation to Areas of CE 
 
 In April 2011, a combined CT and angiography system, the so-called IVR-CT (Artis 
Zee Ceiling and Somatom Emotion 16; Siemens, Erlangen, Germany) was installed in 
our institute. This system consisted of flat-panel angiography equipment and a 16-row 
multidetector CT, and it replaced the old angiography system (Multistar T.O.P.; 
Siemens).  With this IVR-CT apparatus, CT during arterial portography (CTAP) and 
two-phase CTHA were routinely obtained before TACE, and plain CT was obtained at 
the end of TACE to confirm the distribution of LPD.  Parameters of CTAP and CTHA 
were as follows; 0.5 mm collimation, 1.5 mm reconstruction, pitch 0.8, 120kVp, and 
Auto-mAs.  A total of 100 mg I/mL contrast medium with a total volume of 120 mL 
was injected into the superior mesenteric artery at a rate of 6 mL/s, and CTAP was 
obtained with a 30 sec delay time.  For CTHA, the same contrast medium as that for 
CTAP was injected into proper or common hepatic artery at a rate of 2-3 mL/s, and 
the first phase was obtained with a 5 s delay time. The total volume of contrast medium 
was defined so that the injection lasts until the first phase scanning was completed.  
The second phase was started in 10 s after the completion of the first-phase scan.  
CE was defined as areas surrounding HCC with stronger enhancement than 
nontumorous liver parenchyma, with the tumor per se revealing less enhancement 
corresponding to washout, as observed on the second phase of CTHA [7, 13].    
  For the patients in the W group who underwent TACE with a sufficient amount of 
warmed MPT-LPD in the IVR-CT system, HCCs with apparent CE, as observed on 
the second phase of CTHA, were retrospectively selected by two radiologists in 
consensus who were blinded to the patients’ information.  The areas of CE and of 
LPD accumulation as observed by distribution of LPD were compared, and their 
degree of concordance was subclassified into three grades (Fig. 2). Grade 1 indicated 
no accumulation of MPT-LPD in CE, grade 2 partial coverage of CE by MPT-LPD, 
and, grade 3 complete and sufficient coverage of CE by MPT-LPD.  This 
assessment was carried out not only on axial dimension, but also three-dimensionally, 
utilizing the multiplanar reconstruction function equipped with our picture archiving 
and communication system (Rapid Eye, Toshiba Medical System, Ootahara, Japan).   
  Finally, the degree of LPD-CE concordance (grades 1-3) and that of short-term 
treatment effects (TE1-TE4) were also correlated.   
Results 
Assessment of the intraarterial appearance of MPT/LPD 
 
There were seven branches in five patients in RT group and 36 branches in 18 
patients in W group for this evaluation.  Demographic data of the two groups are 
listed in Table 1.  There was no difference between the groups in age, sex, largest 
tumor size, and level of liver dysfunction.    
The samples of morphological grades 1, 2, 3, 4, and 5 were, respectively 4, 0, 1, 2, 
and 0 for RT group, and 1, 2, 11, 18, and 4 for W group, revealing a statistically 
significant difference between the groups, with W group demonstrating higher grades 
than the RT group (p = 0.015 ＜ 0.05, Mann-Whitney U test).  In other words, 
warmed MPT-LPD tended to result in smooth, continuous features, whereas MPT-
LPD at room temperature exhibited a beaded or globular appearance.  
Representative cases are shown in Fig. 3.    
 
 
Short term local therapeutic effect assessed on follow-up CT  
 
The demographic data of the two groups that underwent follow up CT are listed in 
Table 2.  There were 17 HCC nodules in 9 patients in the RT group, and 51 HCC 
nodules in 25 patients in the W group that met the inclusion criteria for this 
evaluation.  There was no difference between the groups in age, sex, the largest 
tumor size, and level of liver dysfunction.  No significant difference was observed in 
the period from TACE to discharge, or in the maximum C-reactive protein level after 
TACE.  The period between TACE and follow-up CT was slightly shorter in RT 
group (Table 2).  The TE1, TE2, TE3, and TE4 degrees of LPF accumulation were 
respectively, 6, 3, 8, and 0 for the RT group, and 15, 5, 10, and 21 for the W group, 
which was a statistically significant difference (p＜0.05, Mann-Whitney U test). 
That is , the W group exhibited significantly better short-term therapeutic effect 
than the RT group.  Representative cases are shown in Figs. 4.  
 
 
Evaluation of LPD Distribution Immediately after TACE in Correlation to CE 
 
There were 29 HCCs in 16 patients that demonstrated apparent CE on the second 
phase of CTHA and that were treated with sufficient amount of warmed MPT-LPD.  
There were 13 men and three women aged 70 ± 10 years.  The size of the tumors 
was 15 ± 9.2 mm.  Child-Pugh grades were A, B, and C scores were , respectively, 
8, 8, and 0 (6.5 ± 1.4).   
As for the 29 lesions, the concordance of LPD accumulation and CE were 2, 8, and 
19 for grades 1, 2, and 3, respectively.  Namely, in 66 % (19 of 29) of HCC nodules 
demonstrating apparent CE, MPT-LPD completely covered CE of the nodules.  
  Finally, the degree of LPD-CE concordance (grades 1-3) and that of short term 
treatment effects (TE1-TE4) were significantly correlated (ρ = 0.434, p = 0.022, 
Spearman’s rank correlation) (Table 3).  In other words, the more complete 
coverage of CE by MPT-LPD, the better the short-term therapeutic effect.  
Representative cases are shown in Fig. 4. 
.  
Discussion 
In our previous report [5], we demonstrated that warming MPT-LPD to 40 ℃ 
reduces its viscosity to almost one half of that at room temperature (25℃), and it 
also reduces the pressure required to inject the substance through microcatheters.  
In the current study, we first confirmed that warmed MPT-LPD exhibited a more 
smooth and continuous appearance immediately after injection into arteries compared 
to MPT-LPD at room temperature. This indicates warmed MPT-LPD may behave , 
for example, more like liquid contrast medium, which smoothly and continuously 
distributes within the vascular lumen.  The viscosity of iodine contrast medium 
(350-370 mg I/mL) at 37 ℃ have been reported to be approximately 10 mPa/S 
[14].  Another possible mechanism for these findings is the difference in the 
injection rate.  Because we did not use a consistent injection rate during MPT-LPD 
injection, but rather paid attention to not causing regurgitation under fluoroscopy 
guidance, it was possible that less viscosity in W groups resulted in more rapid 
injection, and thus a continuous appearance.   
Our data also suggested that more than 60% of warmed MPT-LPD may pass through 
the tumor sinusoids of HCC and reach around the tumor at the areas of CE.  
According to Terayama et al. [7], emulsion of epirubicine and LPD reached the areas 
of CE via tumor sinusoids in 64% of the HCC nodules demonstrating apparent CE; 
they considered that this may represent the mechanism of embolization of both the 
arterial and portal sides of the tumor, leading to an excellent antitumor effect.  Our 
data with warmed MPT-LPD are at least comparable to theirs, although the 
backgrounds of the treated lesions are not identical.  We also confirmed that the 
more complete the coverage of CE by MPT-LPD, the better short-term therapeutic 
effect.   
Thus, we might reasonably infer from our results that warmed MPT-LPD with 
reduced viscosity flowed smoothly within the vascular lumen, passing through the 
tumor sinusoids to the portal venous sides of the tumor, resulting in better short-
term therapeutic effect than that at room temperature.  
Nevertheless, our results were not satisfactory: although warming MPT-LPD greatly 
improved its short-term therapeutic effect, there are still several examples of poor 
response (TE1) in patients treated with warmed MPT-LPD.  This may at least partly 
be attributable to the cooling effect of warmed MPT-LPD during the procedure. To 
solve this problem, some devices that will keep the injection syringes warm while 
under sterile condition may need to be developed.  However, considering that seven 
of 18 nodules (more than one third) demonstrating complete coverage of CE by 
MPT-LPD (grade 3) resulted in TE1, improvement in the delivery of embolic 
materials may also be required.  Further investigation is needed to clarify these 
issues.    
There are several limitations to this preliminary clinical study, including its 
retrospective nature.  We did not evaluate the concordance between MPT-LPD 
distribution and CE in the RT group, but only in the W group.  This is because we 
already had some data suggesting inferiority of the RT group in terms of the local 
control rate. After we installed the IVR-CT apparatus, it was ethically inappropriate 
to perform MPT-LPD TACE at room temperature as a control.  This is also a 
reason why we could not increase the number of control subjects (that is, RT group) 
in this study.  Our short follow-up period is another limitation.  Further, we only 
compared MPT-LPD delivered warmed and at room temperature; we did not compare 
conventional chemotherapy agents in this study. To address these limitation, We 
have begun a prospective study comparing TACE performed with warmed MPT-LPD 
and TACE performed with epirubicine in a selected patient group in our institute. 
  In conclusion, MPT-LPD warmed to 40 ℃ flowed smoothly within the vascular 
lumen and reached the portal venous sides of the tumor in 60% of the cases, 
presumably passing through the tumor sinusoids.  TACE with warmed MPT-LPD 
provided significantly better local control of HCC at short-term observation 
compared to room-temperature MPT-LPD.  Warming MPT-LPD may prove to be a 
simple and promising method that contributes to the therapeutic effect of MPT-LPD 
in HCC.  
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Figure legends 
Fig. 1 Grading system for the assessment of the intraarterial appearance of MPD-LPD 
suspension, ranging from the discontinuous, beaded appearance of grade 1 to the 
smooth, continuous appearance of grade 5   
Grade 1              Grade 2              Grade 3 
 
 
 
Grade 4              Grade 5  
 
 
 
 
 
Fig. 2 Grading system for the assessment of the concordance between CE and LPD 
accumulation, with no, partial, and complete coverage of CE by LPD, corresponding 
to grades 1, 2, and 3, respectively.  T represents the main body of the tumor.  The 
yellow zone around T represents the area of CE;  the shaded circle in the lower row 
represents LPD accumulation 
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Fig. 3  Intraarterial appearance of MPD-LPD suspension immediately after injection 
A  RT group (67-year-old man).  Injection from the posterior branch.  Note globular 
or beaded appearance, which was categorized as grade 2 
A 
T T T 
 B  W group (70-year-old man). Injection from the anterior branch.  Note smooth and 
continuous appearance as compared to Fig. 3a, which was categorized as grade 4 
B 
 
 
Fig. 4  Short-term therapeutic effect in 69-year-old man in the W group. 
A  Arterial phase CT 1 month before treatment shows 3 cm enhancing nodule with 
necrotic component (arrow). 
 B  Second phase of CT during CTHA.  Thin CE is seen surrounding the tumor 
(arrowhead).  Necrotic component remains low dense (arrow). 
C  Plain CT immediately after treatment. Sufficient LPD covers the whole CE, 
suggesting grade 3 LPD accumulation.  No LPD accumulation is seen at the necrotic 
part (arrow) 
D  Arterial phase CT 2 months after the treatment.  Note complete accumulation of 
LPD throughout the nodule and the decrease in size of the lesion.  Necrotic 
component remains low dense (arrow); TE4 was assigned 
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Table 1  Demographic data of the two groups that underwent transarterial 
chemoembolization with MPD-LPD at room temperature (RT group) and with warmed 
MPD-LPD (W group) to assess the intraarterial appearance within the vascular lumen 
 
 RT group 
(7 branches in 5 patients) 
W group 
(36 branches in 18 patients) 
 
age 67 ± 6.2 74 ± 6.9 NS* 
sex  M:F = 4:1 M:F = 13:5 NS** 
CP score 5.6 ± 0.5 6.3 ± 1.1 NS* 
CP grade A/B/C = 5/0/0 A/B/C = 10/8/0 NS** 
  
RT: transarterial chemoembolization using miriplatin at room temperature 
W: transarterial chemoembolization using warmed miriplatin 
CP: Child-Pugh 
 
*unpaired t-test 
** Fisher’s exact probability test 
Table 2  Demographic data of RT and W groups for short-term local therapeutic 
effect compared by follow-up computed tomography 
 
 RT group 
(17 nodules in 9 patients) 
W group 
(51 nodules in 25 
patients) 
 
sex  M:F=6:3  M:F=16:9  NS a  
age  67 ± 8  72 ± 9  NS b  
Initial vs rec.  5:4  14:11  NS a  
HCC size (mm)  17.6±7.8  20.8±13.6  NS b  
CP grade   A/B/C=8/1/0  A/B/C=13/12/0  NS c  
CP score  5.7± 0.6  6.4 ± 1.5  NS c  
TACE-CT （Mo）  1.6 ± 0.4  2.5 ± 1.6  p <.05  
Hosp. period （D）  13.1 ± 5  10.9 ± 2.4  NS b  
Max. CRP (mg/dl)  7.2 ± 5.5  3.6 ± 4.5  NS c
 
 
 
MPT-LPD miriplatin-lipiodol suspension, HCC hepatocellular carcinoma,  
CRP: C-reactive protein, TACE-CT: interval between TACE and follow-up 
computed tomography, 
CRP maximum serum C-reactive protein level after TACE 
a  Chi-square test  b unpaired t test  c unpaired t test, marginal 
Table 3  Correlation between the lipiodol-corona enhancement concordance grades  
and the short-term therapeutic effects in 29 nodules 
 
 TE1 TE2 TE3 TE4 
Grade 1 2 0 0 0 
Grade 2 3 1 1 4 
Grade 3 7 0 1 10 
 
TE1 tumor enlargement more than 25%;   
TE2 tumor response between TE1 and TE3;  
TE3 tumor necrosis or dense lipiodol (PLD) accumulation of more than 50%;   
TE4 difuse accumulation of LPD associated with tumor size reduction, suggesting 
100% tumor necrosis 
ρ = 0.434, p = 0.022,  Spearman’s rank correlation 
 
 
